These findings indicate that SIGLEC9 could serve as a diagnostic marker for poor prognosis in cervical cancer and may emerge as a promising target for immunotherapy in future treatment strategies for cervical cancer patients. The gene discussed is SIGLEC9; the disease is cervical cancer.